Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with
APS-1 | Journal of Experimental Medicine | Rockefeller University Press Skip to Main Content …

Autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) are found in the blood of at
least 15% of unvaccinated patients with life-threatening COVID-19 pneumonia. We report …

INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …

Type‐I interferons (IFNs) mediate antiviral activity and have emerged as important immune
mediators during coronavirus disease 19 (COVID‐19). Several lines of evidence suggest …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …

Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …

Since December 2019, over 150 million individuals have been infected with SARS-CoV-2
globally. While most cases (> 95%) are asymptomatic or mild, a small proportion develop …

Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1: 10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID …

Objectives Impairment of type I interferon (IFN‐I) immunity has been reported in critically ill
COVID‐19 patients. This defect can be explained in a subset of patients by the presence of …

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19
pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring …